Novartis CEO boss Narishiman stated that the company will not compete in the weight loss drug market frenzy dominated by Novo ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals. Novartis Pharm. Corp. v. MSN Pharm. Inc., Civil Action No ...

We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim ...

1-4 London, 4 September 2024 - Today, Novartis announced that the National Institute for Health and Care Excellence (NICE) has published final technology appraisal guidance, recommending Fabhalta® ...

Recursion Pharmaceuticals Inc RXRX shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).

The workers of Square Pharmaceutical have blocked the Dhaka-Tangail highway with 21-point demands including salary increase, job stabilization, and two-day weekend. The workers of Square ...

Lindy Biosciences has announced an exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG. The deal centres on Lindy’s microglassification technology, which ...

The Indian pharmaceutical industry is expected to witness significant growth by 2030, driven by new regulatory measures and technological advancements, according to a report from Pharmarack ...

Natco Pharma has submitted to the U.S. Food and Drug Administration an abbreviated new drug application for a generic version of Novartis’ cancer drug Tabrecta (capmatinib hydrochloride).

Novartis secured worldwide rights to Leqvio under a licensing and collaboration agreement with Alnylam Pharmaceuticals. Novartis Development president and chief medical officer Shreeram Aradhye said: ...